Data Year:

For its 2025 fiscal year, MYRIAD GENETICS INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Mark S. Verratti
Chief Operating Officer
Total Compensation $3,145,251 View details Pay Rank By Title In Biotechnology industry #58 View more
Paul J. Diaz
Former President and Chief Executive Officer
Total Compensation $688,637 View details Pay Rank By Title In Biotechnology industry #708 View more
Samraat S. Raha
President and Chief Executive Officer
Total Compensation $5,686,740 View details Pay Rank By Title In Biotechnology industry #226 View more
Dale Muzzey Ph.D.
Chief Scientific Officer
Total Compensation $1,862,912 View details Pay Rank By Title In Biotechnology industry #34 View more
Scott J. Leffler
Former Chief Financial Officer
Total Compensation $2,736,493 View details Pay Rank By Title In Biotechnology industry #164 View more
Margaret Ancona
Former EVP, Strategy and Transformation
Total Compensation $1,895,165 View details Pay Rank By Title In Biotechnology industry #117 View more
Brian J. Donnelly
Chief Commercial Officer
Total Compensation $6,000,145 View details Pay Rank By Title In Biotechnology industry #20 View more
Benjamin R. Wheeler
Chief Financial Officer
Total Compensation $1,507,897 View details Pay Rank By Title In Biotechnology industry #290 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at MYRIAD GENETICS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. MYRIAD GENETICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. MYRIAD GENETICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Mark S. Verratti
Chief Operating Officer
Total Cash $1,061,206 Equity $2,058,069 Other $25,976 $3,145,251
Paul J. Diaz
Former President and Chief Executive Officer
Total Cash $418,103 Equity $0 Other $270,534 $688,637
Samraat S. Raha
President and Chief Executive Officer
Total Cash $1,671,561 Equity $3,989,729 Other $25,450 $5,686,740
Dale Muzzey Ph.D.
Chief Scientific Officer
Total Cash $728,077 Equity $1,121,054 Other $13,781 $1,862,912
Scott J. Leffler
Former Chief Financial Officer
Total Cash $393,798 Equity $1,067,674 Other $1,275,021 $2,736,493
Margaret Ancona
Former EVP, Strategy and Transformation
Total Cash $330,850 Equity $800,754 Other $763,561 $1,895,165
Brian J. Donnelly
Chief Commercial Officer
Total Cash $1,171,910 Equity $4,801,898 Other $26,337 $6,000,145
Benjamin R. Wheeler
Chief Financial Officer
Total Cash $733,914 Equity $759,229 Other $14,754 $1,507,897
For its 2025 fiscal year, MYRIAD GENETICS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Samraat S. Raha CEO Pay $5,820,074 Median Employee Pay $97,407 CEO Pay Ratio 60:1
For its 2024 fiscal year, MYRIAD GENETICS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Colleen F. Reitan Total Cash $443,499
Daniel K. Spiegelman Total Cash $38,198
Daniel M. Skovronsky, M.D., Ph.D. Total Cash $433,499
Heiner Dreismann, Ph.D. Total Cash $443,499
Lee N. Newcomer, M.D. Total Cash $447,999
Mark S. Davis Total Cash $349,997
Paul Bisaro Total Cash $449,345
Rashmi Kumar Total Cash $433,499
S. Louise Phanstiel Total Cash $563,499
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.